Treatment of Major Depressive Disorder in Japanese Patients with Cancer: A Matched Cohort Study Using Employer-Based Hea
- PDF / 697,556 Bytes
- 11 Pages / 595.276 x 790.866 pts Page_size
- 97 Downloads / 203 Views
ORIGINAL RESEARCH ARTICLE
Treatment of Major Depressive Disorder in Japanese Patients with Cancer: A Matched Cohort Study Using Employer‑Based Health Insurance Claims Data Tatsuo Akechi1 · Shinji Fujimoto2 · Izumi Mishiro2 · Katsuhito Murase2 Accepted: 7 October 2020 © The Author(s) 2020
Abstract Background and Objective Patients with cancer are at high risk of major depressive disorder (MDD), but little is known about their MDD treatment. We investigated the use of antidepressants and other drugs for MDD after cancer diagnosis, and patient characteristics associated with their use. Methods Adults with a new cancer diagnosis were matched to cancer-free patients using a Japanese employee health insurance database (JMDC); this exploratory analysis included only cohort patients diagnosed with MDD between 6 months before and 12 months after the cancer diagnosis index month. Initial prescription frequencies of antidepressants and other MDD medications were compared between cancer and cancer-free groups and analyzed according to age, sex, and hospital characteristics. Results Compared with the cancer-free group (n = 4097), significantly fewer patients in the cancer group (n = 1199) were prescribed antidepressants {622 (51.9%) [95% CI 49.0–54.7] vs 2385 (58.2%) [95% CI 56.7–59.7]}, particularly selective serotonin reuptake inhibitors. In contrast, prescription of other medications, especially antipsychotics and anxiolytics (tandospirone, hydroxyzine), was more frequent in the cancer group than in the cancer-free group. In the cancer group, women were prescribed antidepressants (mostly selective serotonin reuptake inhibitors) and other medications (mostly benzodiazepines) more than men. Antidepressant prescription decreased with age; patients aged
Data Loading...
